Question 1

What Is Body Pharm Semaglutide 6 Pen?

Accepted Answer

Body Pharm Semaglutide 6 Pen is a compounded or research-grade semaglutide injection pen marketed online in South Africa as containing 6 mg of semaglutide total per pen, intended for once-weekly subcutaneous injection across a multi-week titration. The concentration in mg/mL and the cartridge volume are not disclosed on either the Beskinny or MyAntidote product pages. No independent lab analysis has been published, so the “6 mg” figure is the marketed total content rather than an independently verified specification.

Semaglutide is a GLP-1 receptor agonist—it binds to glucagon-like peptide-1 receptors in the body, mimicking endogenous GLP-1. That triggers insulin release from the pancreas only when blood glucose is elevated (glucose-dependent), suppresses glucagon, slows gastric emptying, and acts on appetite centres in the brain to reduce hunger. That combination drives both the glycaemic effect in type 2 diabetes and the weight loss seen in obesity trials.

The Body Pharm pen is not the same as Novo Nordisk’s Ozempic (semaglutide for type 2 diabetes) or Wegovy (semaglutide 2.4 mg for obesity). Branded pens are manufactured under Novo Nordisk’s quality system. The 6 mg total is structured to span a roughly 6–8 week early titration (0.25 mg → 0.5 mg weekly) rather than to deliver a single dose.

Question 2

Who Should Consider Semaglutide for Weight Loss?

Accepted Answer

Semaglutide is clinically appropriate for adults with a BMI ≥30 kg/m² (obesity), or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia. Outside those thresholds, the risk-benefit calculation shifts against pharmacotherapy regardless of which pen you’re looking at.

There are firm contraindications. Semaglutide should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), during pregnancy or while planning pregnancy, or by anyone with known hypersensitivity to semaglutide or its excipients. A history of pancreatitis, severe gastroparesis, or active gallbladder disease warrants a direct conversation with your doctor before starting.

Question 3

Is Body Pharm Semaglutide 6 Pen the same as Ozempic?

Accepted Answer

No. Ozempic is a semaglutide product manufactured by Novo Nordisk and indicated for type 2 diabetes. They are not bioequivalent. No independent lab analysis of the Body Pharm pen has been published.

Question 4

How long does one Body Pharm Semaglutide 6 Pen last?

Accepted Answer

A 6 mg pen lasts roughly 16–24 weeks depending on titration. At the typical escalation of 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg weekly, one pen covers about 4 months before reaching higher maintenance doses. The exact mL/mg-per-click concentration is not published by the supplier.

Question 5

What is the difference between the 3 Pen and 6 Pen versions?

Accepted Answer

The number refers to total semaglutide content: a 3 Pen contains 3 mg, a 6 Pen contains 6 mg. The Semaglutide 2mg GLP-1 (Buy 1 Get 2 Free) bundle delivers 6 mg total across three pens. Higher-content options like the HD Semaglutide 10 Pen extend duration further.

Detail	Body Pharm Semaglutide 6 Pen
SKU	pepsem6
Active compound	Semaglutide (GLP-1 receptor agonist)
Listed strength	6 mg
Format	Dial-a-dose pen
Pack contents	1 pen, 8 needles
Alcohol swabs	Not included — supply separately
Availability	InStock
Intended use	Prescription-class compound supplied for research use

Body Pharm Semaglutide 6 Pen

Body Pharm Semaglutide 6 Pen: price and pack

Verification before purchase

Delivery, payment and support

How to order

Reviews